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Abstract
Purpose AZD5363 is a potent pan-AKT inhibitor originally formulated as a capsule; a tablet was developed for patient 
convenience and manufacturing ease. This study assessed the PK comparability of both formulations (Part A) and the effect 
of food (Part B) on the PK/safety of the tablet.
Methods Adults with advanced solid tumours received AZD5363 480 mg bid in a partially fasted state by tablet (Week 1) 
and capsule (Week 2) in a ‘4-days-on/3-days-off’ schedule (Part A). PK parameters were evaluated using pre-defined 90% 
CIs for AUCτ and Cmax ratios of 0.75–1.33 to assess comparability. In Part B, AZD5363 tablet was given to a new cohort of 
patients under the same conditions as Part A, except on the morning of PK assessment days, when it was administered after 
an overnight fast (Week 1) and standard meal (Week 2).
Results In evaluable patients (N = 11), the geometric least-squares mean ratios (tablet:capsule) for AUCτ and Cmax were 
0.90 (0.77–1.06) and 1.02 (0.86–1.20), respectively, demonstrating comparable PK in the partially fasted state. Tablet and 
capsule safety data were also comparable. Tablet PK profiles indicated later  tmax and lower Cmax after food versus overnight 
fast. Fed and fasted AUCτ and Cmax ratios were 0.89 (0.76–1.05) and 0.67 (0.55–0.82), respectively (N = 9). The safety/
tolerability profile of the tablet was comparable between fed and fasted states.
Conclusions PK and safety/tolerability of AZD5363 tablet and capsule were comparable. Food did not affect the bioavail-
ability of AZD5363, but reduced the absorption rate without discernibly affecting safety/tolerability.
Keywords AZD5363 · AKT inhibitor · Capsule · Tablet · Fed:fasted · Advanced solid tumour
Introduction
The phosphoinositide 3-kinase/serine–threonine protein 
kinase AKT/mammalian target of rapamycin (PI3K/AKT/
mTOR) signalling pathway is frequently deregulated in 
human cancer [1] and is therefore a promising target for 
the development of new therapies [2, 3]. As a key com-
ponent of the signalling network that mediates processes 
such as cell proliferation and resistance to apoptosis, AKT 
(expressed in three isoforms: AKT1, 2 and 3) has been 
shown to be overexpressed or activated in a wide range of 
solid and haematological malignancies [3, 4]. Activation 
of all three isoforms of AKT is associated with anticancer 
drug resistance, advanced disease and poor prognosis [5]. 
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Several diverse small molecule compounds, such as ATP-
competitive inhibitors, phosphatidylinositol analogues 
and allosteric inhibitors, have been developed to block 
the AKT pathway, but while effective inhibition has been 
shown at nanomolar concentrations, non-selective target-
ing of other protein kinases (including PKA and PKC) 
limits the therapeutic utility of some treatments [3].
AZD5363 is a potent, selective inhibitor of AKT1, 2 
and 3 [6, 7]. Preclinical studies of single and chronic oral 
dosing of AZD5363 in mice have demonstrated dose-
dependent inhibition of AKT substrate phosphorylation 
(GSK3β and PRAS40), tumour cell proliferation, and 
tumour growth in xenograft models [6]. Furthermore, 
increasing evidence supports the antitumour efficacy of 
AZD5363 in overcoming or delaying resistance to hor-
mone therapy, chemotherapy or HER2-directed therapies 
in patient-derived gastric, breast and prostate cancer xeno-
graft models [6, 8–10]. Antitumour activity of AZD5363, 
established across a range of preclinical models, has been 
reported in Phase 1, open-label clinical studies in patients 
with solid tumours as monotherapy and in combination, 
which were conducted with the primary objectives of eval-
uating the safety, tolerability, pharmacokinetic (PK) and 
pharmacodynamic (PD) effects of AZD5363 under adapt-
able dosing schedules [11–14]. From these studies, rec-
ommended Phase 2 doses were established for AZD5363 
monotherapy in a ‘4-days-on/3-days-off’ schedule (4/3 
schedule; 480 mg twice daily [bid]), as well as a ‘2-days-
on/5-days-off’ schedule (2/5 schedule; 640 mg bid) [11, 
13, 14]. With the 4/3 schedule, PK results were compara-
ble to exposures associated with tumour regression in pre-
clinical models. AZD5363 plasma exposure was approxi-
mately dose proportional in the dose range 80–800 mg and 
terminal half life was approximately 10 h [11]. The major 
elimination route is assumed to be hepatic, as less than 
10% of the dose was excreted in urine as unchanged drug. 
The observed adverse events (AEs) of diarrhoea, rash and 
hypersensitivity, and hyperglycaemia were consistent with 
the effects of AKT inhibition [11, 13, 14].
AZD5363 was administered to patients in the early clini-
cal trial programme as a capsule formulation in a partially 
fasted state (no caloric intake from 2 h before dosing to 1 h 
after dosing). However, for patient convenience and ease of 
manufacturing, a tablet formulation has now been devel-
oped. Before widespread introduction of the tablet formula-
tion into the clinical programme, PK comparability with the 
capsules needed to be verified. Furthermore, an investigation 
of the effect of food and an overnight fast would inform dos-
ing recommendations. Consequently, this two-part Phase 1 
study was performed to determine whether the capsule and 
tablet formulations of AZD5363 are comparable in terms of 
PK exposure to compare the safety and tolerability profiles 
of the two formulations (Part A), and to make a preliminary 
assessment of the effect of food on the PK, safety and toler-
ability of the tablet formulation (Part B).
Methods
Study design
This was an open-label, multicentre, two-part, fixed-
sequence, crossover study of AZD5363 in adult patients with 
advanced solid malignancies, which was conducted between 
December 2013 and July 2015 at two sites in the UK and 
one in the Netherlands (ClinicalTrials.gov NCT01895946; 
AstraZeneca study name, OAK). The trial was performed 
in accordance with the principles of the Declaration of Hel-
sinki, Good Clinical Practice and the AstraZeneca policy on 
bioethics [15]. The local ethics committee or independent 
review board at each investigator site approved the protocol 
prior to study commencement. All patients provided written 
informed consent prior to study participation.
In Part A, AZD5363 tablet (Week 1) and capsule (Week 
2) forms were given orally at 480 mg bid in a 4/3 schedule 
(i.e. 4 days on treatment, 3 days off treatment). AZD5363 
tablet or capsule was taken at approximately the same time 
in the morning and evening, in a partially fasted state (from 
2 h before until 1 h after each dose). PK parameters were 
assessed on the fourth day of Week 1 and Week 2 (i.e. on 
Day 4 and Day 11).
In Part  B, which occurred following completion of 
Part A, a new cohort of patients received the AZD5363 tab-
let at the same dose and schedule as in Part A. In Week 1, 
AZD5363 tablet was administered in a partially fasted state 
except on PK assessment Day 4, when fasting was overnight 
(minimum of 8 h) until 4 h post-dose. In Week 2, AZD5363 
tablet was administered in a partially fasted state, except on 
PK assessment Day 11 in Week 2, when the morning dose 
was given in a fed state. The tablet was administered 30 min 
after starting a standardized meal containing 605 kcal, of 
which 24% (36 g) were from proteins, 26% (18 g) from fat 
and 50% (76 g) from carbohydrates. Patients had been fast-
ing overnight prior to the breakfast and no further food was 
permitted for 4 h post-dose.
From Week 3 onwards, patients received AZD5363 cap-
sule in Part A and AZD5363 tablet in Part B. Both formula-
tions were administered according to the standard dietary 
restrictions for the study treatment (i.e. partially fasted).
In Part A, an initial cohort of six patients was enrolled. 
If this cohort was insufficient to establish comparability of 
dose or PK exposure of the AZD5363 tablet and capsule, 
additional patients could be enrolled (up to a maximum of 
24 patients in total) to further evaluate comparability. In 
Part B, an initial cohort of six patients was enrolled, fol-
lowed by possible further recruitment of up to a maximum of 
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12 patients to explore the effect of food on tablet formulation 
exposure. Cohort expansion, dosing adjustment of the tablet 
formulation, or exploration of changes in the dose schedule 
was considered after review of safety and tolerability and PK 
data by the scientific review committee. For both Parts A and 
B, patients received AZD5363 for as long as they continued 
to show clinical benefit, as judged by the investigator, and 
in the absence of disease- or treatment-related discontinu-
ation criteria.
Patient selection
Eligible patients were aged ≥ 18 years and had a confirmed 
(histologically or, where appropriate, cytologically) malig-
nant solid tumour refractory or resistant to standard therapy 
or for which no suitable standard therapy existed. Patients 
were required to have a World Health Organization (WHO) 
performance status of 0 or 1, with no clinical deterioration 
in the previous 2 weeks and a life expectancy of at least 12 
weeks. Willingness to fast and to eat the standardized meal 
was a further requirement for entry into Part B of the study.
Exclusion criteria included treatment with chemotherapy, 
immunotherapy, anticancer agents, and specific CYP3A4 
inducers/inhibitors/substrates or CYP2D6 substrates, or 
nitrosourea or mitomycin C up to 6 weeks prior to commenc-
ing study treatment; major surgery or radiotherapy within 4 
weeks of initiation of study treatment; clinically significant 
glucose metabolic abnormalities; severe or uncontrolled sys-
temic disease; pre-specified cardiac conditions; inadequate 
bone marrow reserve or organ function; and hypersensitivity 
to AZD5363 or drugs with similar chemical structure. In 
addition, patients with a significant gastrointestinal condi-
tion that precluded fasting or ingestion of the standardized 
meal were excluded from Part B.
Study objectives
Co-primary objectives of the study were to assess the PK 
exposure of the AZD5363 tablet and the capsule (Part A) 
and to investigate the effect of a standardized meal on the 
PK exposure of the AZD5363 tablet (Part B). Secondary 
objectives included to generate multiple-dose PK data 
for the AZD5363 tablet and capsule (Part A) and for the 
AZD5363 tablet in the presence/absence of food (Part B); 
and to explore the safety/tolerability of the AZD5363 tablet 
and capsule (Part A) and the effect of food on the safety/
tolerability of the AZD5363 tablet (Part B).
Assessments
PK profiles of AZD5363 tablet and capsule formulations 
were characterized from venous blood samples drawn pre-
dose and 0.5, 1, 2, 4, 6, 8 and 12 h after the morning dose 
on Day 4 and Day 11 in Parts A and B. In addition, pre-dose 
samples were drawn on Day 8 in Part B to verify that a wash-
out period of 3.5 days was adequate for AZD5363.
The bioanalytical method used to generate AZD5363 
plasma concentration data for the derivation of PK parame-
ters for the study had been previously validated, according to 
regulatory guidance [16, 17], by Covance UK Ltd on behalf 
of AstraZeneca. Following the addition of internal stand-
ard  ([13C6]AZ12886380), calibration, quality control (QC) 
and study samples (25 µL) were processed by solid-phase 
extraction then assayed for AZD5363 by liquid chromatog-
raphy–tandem mass spectrometry. The lower limit of quanti-
fication of the assay was 1.00 ng/mL, with the assay demon-
strating linearity up to 1000 ng/mL. Although the majority 
(> 67%) of samples assayed had concentrations within the 
validated assay range, any samples found or expected to have 
concentrations in excess of the validated assay range were 
appropriately diluted in control plasma prior to extraction 
and re-assayed/assayed with dilution QC samples included 
to validate the dilution scheme on a batch-by-batch basis. 
All trial samples were analysed within the known stabil-
ity period for AZD5363 and all a priori assay acceptance 
criteria were met, in accordance with regulatory guidance.
Primary PK parameters assessed included the area under 
the plasma concentration–time curve during the 0- to 12-h 
dosing interval (AUCτ), maximum concentration (Cmax), 
minimum concentration (Cmin), and time to maximum con-
centration (tmax). PK parameters were derived using non-
compartmental methods  (Phoenix®  WinNonlin®). Plasma 
concentration–time profiles were analysed to determine 
Cmax, Cmin and tmax, while AUCτ was determined from appli-
cation of the linear-up/log-down trapezoidal rule.
Safety assessments throughout the study encompassed the 
incidence and severity of AEs (graded according to Com-
mon Terminology Criteria for Adverse Events [CTCAE] 
version 4.0), in addition to laboratory parameters (haema-
tology, clinical chemistry, urinalysis), physical examina-
tion, 12-lead electrocardiography (ECG), and vital signs. 
To assess safety in the fed versus fasted state, the period 
during and just after the fasted day was considered relevant 
to the fasted dose (Days 4–7), and similarly, the fed day and 
subsequent days were considered relevant to the fed state 
(Days 11–14). Any AE occurring after the first dose of study 
treatment and up to 28 days after the last dose of study treat-
ment was included in the AE summaries.
Statistical analysis
Sample size calculations for PK assessment during Part A 
were based on the statistical assumption that within-patient 
mean squared error (MSE) for AUCτ was 0.0289 (log scale), 
with standard deviation (SD) differences of 0.241. Similarly, 
the within-patient MSE calculation for Cmax was assumed to 
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be 0.0484 (log scale), with SD differences of 0.311. Based 
on these assumptions, and a type I error of 5% (for each 
hypothesis), 12 patients were judged sufficient to demon-
strate with at least 80% power that the 90% confidence inter-
vals (CIs) for AUCτ and Cmax would fall entirely within the 
equivalence boundaries of 0.75–1.33, which was considered 
suitable to demonstrate comparability of the two formula-
tions in Part A. No formal sample size calculations were 
performed for Part B, although 12 patients were considered 
appropriate to provide an estimate of the food effect.
A patient was included in the PK analysis set if they had 
taken the drug as required by the protocol on Day 4 and Day 
11 of PK sampling and on the previous 2 days (Part A and 
B), had a full set of PK samples for both tablet and capsule 
(Part A) or for both fasted and fed states (Part B), had fasted 
overnight according to the protocol (Part B) and consumed 
most of the standardized meal within the 30-min time frame 
on Day 11 (Part B).
The statistical analysis for estimating the food and capsule 
effect was based on analysing log-transformed PK param-
eters AUCτ and Cmax using a fixed-effects model with terms 
for patient and treatment only. All statistical calculations and 
analyses were performed with  SAS® software, version 9.1.3 
or higher. Other PK parameters are presented descriptively.
The safety analysis set comprised all patients who 
received at least one dose of AZD5363. All safety data are 
presented descriptively.
Results
Patients
Overall, 18 patients with advanced solid tumours were 
enrolled and received AZD5363 in Part A. Based on the 
results of Part A, the AZD5363 tablet at a dose of 480 mg 
bid in a 4/3 schedule was administered to 12 patients in 
Part B. Baseline demographic and clinical characteristics 
of the enrolled population are summarized in Table 1. All 
patients had metastatic disease. In Part A, the majority of 
patients (10/18, 56%) had primary tumours of gastrointesti-
nal origin (colon, n = 2; colorectal, n = 3; small bowel, n = 1; 
and rectal, n = 4).
Table 1  Patient demographics 
and baseline characteristics in 
Parts A and B
a Includes colon, colorectal, small bowel, and rectal
b Includes adrenal, bladder, liver, other, prostate
c Information not available for one patient in the full set in each part
Patients
PK set Full set
Part A (N = 11) Part B (N = 9) Part A (N = 18) Part B (N = 12)
Median age (range), years 61 (48–70) 63 (42–75) 60 (45–70) 62 (42–75)
Male:female, n:n 6:5 5:4 10:8 5:7
Race, n (%)
 White 10 (90.9) 9 (100) 17 (94.4) 11 (91.7)
 Other 1 (9.1) 0 1 (5.6) 1 (8.3)
Median weight (range), kg 77 (53–115) 81 (65–96) 78 (53–115) 80 (54–96)
WHO performance status, n (%)
 0 5 (45.5) 2 (22.2) 6 (33.3) 2 (16.7)
 1 6 (54.5) 7 (77.8) 12 (66.7) 10 (83.3)
Extent of disease, n (%)
 Metastatic 11 (100) 9 (100) 18 (100) 12 (100)
Primary tumour site, n (%)
 Gastrointestinala 7 (63.6) 2 (22.2) 10 (55.6) 3 (25.0)
 Lung 0 4 (44.4) 1 (5.6) 4 (33.3)
 Breast 0 2 (22.2) 1 (5.6) 2 (16.7)
 Otherb 4 (36.4) 1 (11.1) 6 (33.3) 3 (25.0)
Prior lines of  chemotherapyc, n (%)
 0 0 0 0 0
 1 2 (18.2) 2 (22.2) 3 (16.7) 2 (16.7)
 ≥ 2 9 (81.8) 7 (77.8) 14 (77.8) 9 (75.0)
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Pharmacokinetics
Geometric mean plasma concentration–time profiles from 
both study parts (Parts A and B) are shown in Fig. 1 and 
individual PK parameters (AUCτ and Cmax) in Fig. 2. The 
primary tumour location did not appear to influence the sys-
temic exposure to AZD5363.
Part A
Overall, 11 patients were evaluable for PK analysis in 
Part A; insufficient amount of study drug was taken by two 
patients, four patients did not provide sufficient samples for 
PK analysis, and one patient did not have their PK samples 
collected according to the protocol time points.
The geometric mean AZD5363 plasma concentra-
tion–time profiles indicated faster absorption from the tab-
let than from the capsule (Fig. 1), supported by the shorter 
observed median times to maximum plasma concentration, 
tmax (Table 2). The geometric means for AUCτ and Cmax at 
steady state were, however, similar between the AZD5363 
tablet and capsule, and the 90% CIs for the tablet and capsule 
ratios of the geometric least-squares mean fell within the 
pre-defined boundaries (0.75–1.33), demonstrating compa-
rable exposure (Table 2). The inter-patient variability (coef-
ficient of variation) in AUCτ was 45 and 48% for the capsule 
and tablet, respectively; the corresponding values for Cmax 
were 40 and 46%. Intra-patient variability was estimated to 
be 20% for AUCτ and 22% for Cmax.
Part B
Of the 12 patients who received treatment in Part B, nine 
were included in the PK analysis population; insufficient 
amount of study drug was taken by one patient, one patient 
did not consume the majority of the standard meal, and one 
patient did not provide sufficient samples for PK analysis.
The geometric mean AZD5363 plasma concentra-
tion–time profiles indicated a time lag in the absorption and 
a lower absorption rate when the tablet was given with food, 
compared with after an overnight fast (Fig. 1). This resulted 
in lower and later peak concentrations (Table 2). For steady-
state Cmax, the lower bound of the 90% CI for the geomet-
ric least-squares mean ratio was outside the boundaries of 
0.75–1.33, but the steady-state AUCτ ratio demonstrated 
comparable extent of exposure (Table 2). The inter-patient 
variability (coefficient of variation) in AUCτ was 17 and 
34% for the fasted and fed administrations, respectively; 
the corresponding values for Cmax were 31 and 23%. Intra-
patient variability was estimated to be 19% for AUCτ and 
23% for Cmax.
Samples collected before dosing on Day 1 contained 
no quantifiable AZD5363. Samples collected pre-dose on 
Day 8 (i.e. 3 days after the last dose on Day 4) contained 
low concentrations (geometric least-squares mean 3.34 ng/
mL) compared with the average steady-state concentration 
over the 12-h dosing interval on Day 11 (geometric mean 
AUCτ/12 = 8136/12 = 678 ng/mL).
Safety and tolerability
Part A
Eighteen patients who received AZD5363 in Part A were 
included in the safety analysis population. The most com-
monly reported AEs, irrespective of causal relationship to 
AZD5363 treatment, were diarrhoea, hyperglycaemia, and 
nausea (Table 3). Only one grade 4 AE was observed during 
the study, which was an event of hypokalaemia with onset 
on Day 16. Hyperglycaemia was the most common overall 
grade 3 AE observed in six patients in the Day 1–7 time 
frame (Table 3).
Nine serious AEs (SAEs) were observed in 7 of 18 
patients (38.9%) in Part A. In two of these patients, the 
events occurred prior to the start of study treatment. SAEs 
Fig. 1  Geometric mean (± SD) 
plasma concentration–time pro-
files for the AZD5363 tablet and 
capsule given partially fasted 
(Part A), and the tablet given 
after an overnight fast and food 
(Part B). Summarizes plasma 
concentrations by nominal 
sample time, and the symbols 
have been staggered for clarity 
of presentation. Geometric 
mean (± SD) is calculated as 
exp(µ ± s), where µ and s are the 
mean and standard deviation of 
the plasma concentrations on 
the  loge scale 0
100
0.5 1 2 4 6 8 12
10,000 Tablet, partial fast (Part A, n=11)
1000
G
eo
m
et
ric
 m
ea
n 
co
nc
en
tr
at
io
n
±
 S
D
 (
ng
/m
L)
Time (hours)
Capsule, partial fast (Part A, n=11)
Tablet, overnight fast (Part B, n=9)
Tablet, fed (Part B, n=9)
878 Cancer Chemotherapy and Pharmacology (2018) 81:873–883
1 3
of mouth haemorrhage, papular rash, and pyrexia were each 
reported in one patient during treatment, and diarrhoea, 
vomiting, pulmonary embolus, and intestinal obstruction 
were each reported by one patient in the follow-up phase. 
Of these SAEs, only papular rash and diarrhoea were con-
sidered to be related to treatment, and only papular rash led 
to treatment discontinuation. Two other patients discontin-
ued treatment because of AEs (nausea, macular rash). Five 
patients had study treatment interruptions as a result of AEs 
during the course of the study, and median relative dose 
intensity was 100% (quartile 1, 94.0%; quartile 3, 100%).
There were no clinically significant changes in ECG find-
ings, vital signs or physical examinations and no clinically 
important, treatment-related trends in clinical chemistry 
parameters. Elevations in plasma glucose (with associated 
increases in plasma insulin and C-peptide) were observed in 
the majority of patients dosed with AZD5363. The profile 
of these elevations appears to be similar for the tablet and 
capsule formulations (Fig. 3a).
Part B
The most common AEs experienced by patients in Part B 
are summarized in Table 4. Six patients experienced 11 
SAEs, which were diarrhoea (n = 3), maculopapular rash 
(n = 2), pneumonia, hyperglycaemia, dyspnoea, stomatitis, 
vomiting, and papular rash (each n = 1). In four patients, 
the SAEs were considered related to AZD5363: diarrhoea 
(n = 2), maculopapular rash (n = 2), stomatitis, and papular 
rash (both n = 1). Three patients discontinued AZD5363 
Fig. 2  Matched pairs of the PK 
parameters AUCτ and Cmax for 
a tablet versus capsule in the 
partially fasted state (Part A) 
and b tablet in the fasted versus 
fed state (Part B). Gmean geo-
metric mean
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Table 2  PK parameters for steady-state AZD5363 in Parts A and B (PK analysis set)
CV coefficient of variation, GLSM geometric least-squares mean, Gmean geometric mean, NC not calculated
a Median (range)
Parameter N Part A
Tablet Capsule Ratio tablet:capsule
Gmean (CV%) Gmean (CV%) GLSM ratio 90% CI
AUCτ, h ng/mL 11 8536 (47.7) 9445 (44.6) 0.90 0.77, 1.06
Cmax, ng/mL 11 1779 (46.2) 1745 (40.2) 1.02 0.86, 1.20
Cmin, ng/mL 11 192.6 (55.6) 271.5 (57.7) NC NC
tmax,  ha 11 1.0 (0.6–2) 2.0 (1–4)
Parameter N Part B
Fasted Fed Ratio fed:fasted
Gmean (CV%) Gmean (CV%) GLSM ratio 90% CI
AUCτ, h ng/mL 9 9116 (16.8) 8136 (33.9) 0.89 0.76, 1.05
Cmax, ng/mL 9 1842 (31.1) 1239 (23.3) 0.67 0.55, 0.82
Cmin, ng/mL 9 218.5 (30.3) 262.3 (58.6) NC NC
tmax,  ha 9 0.6 (0.5–4) 2.0 (2–4.3)
Table 3  AEs observed in Part A 
occurring in ≥ 2 patients in 
either of the first 2 weeks or 
of grade ≥ 3 severity (safety 
population)
a AEs with onset from Day 15 up to 28 days after the date of the last dose of AZD5363
b As assessed by the investigator
Number of patients (%) Tablet (N = 18)
Days 1–7
Capsule (N = 18)
Days 8–14
Capsule (N = 18)
Day 15  onwarda
All Grade ≥ 3 All Grade ≥ 3 All Grade ≥ 3
Any AE (irrespective of causality) 17 (94.4) 8 (44.4) 15 (83.3) 4 (22.2) 16 (88.9) 7 (38.9)
Any AE (causally  relatedb) 17 (94.4) 7 (38.9) 12 (66.7) 4 (22.2) 14 (77.8) 6 (33.3)
AE by preferred term (irrespective of causality)
 Diarrhoea 11 (61.1) 1 (5.6) 6 (33.3) 0 9 (50.0) 5 (27.8)
 Hyperglycaemia 7 (38.9) 6 (33.3) 4 (22.2) 1 (5.6) 2 (11.1) 1 (5.6)
 Nausea 4 (22.2) 0 2 (11.1) 0 3 (16.7) 0
 Anaemia 1 (5.6) 0 3 (16.7) 0 0 0
 Pyrexia 0 0 3 (16.7) 0 0 0
 Rash maculopapular 0 0 2 (11.1) 2 (11.1) 0 0
 Fatigue 3 (16.7) 0 0 0 4 (22.2) 2 (11.1)
 Constipation 2 (11.1) 0 0 0 1 (5.6) 0
 Vomiting 2 (11.1) 0 0 0 5 (27.8) 0
 Tumour pain 1 (5.6) 1 (5.6) 0 0 0 0
 Blood bilirubin increased 0 0 2 (11.1) 0 0 0
 ECG QT prolonged 0 0 2 (11.1) 0 0 0
 Hypokalaemia 1 (5.6) 0 1 (5.6) 0 2 (11.1) 1 (5.6)
 Hyponatraemia 0 0 1 (5.6) 1 (5.6) 0 0
 Dyspnoea 0 0 0 0 2 (11.1) 1 (5.6)
 Pulmonary embolism 0 0 0 0 1 (5.6) 1 (5.6)
 Intestinal obstruction 0 0 0 0 1 (5.6) 1 (5.6)
 Rash macular 0 0 0 0 1 (5.6) 1 (5.6)
 Rash papular 0 0 1 (5.6) 1 (5.6) 0 0
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Fig. 3  a Glucose profiles 
following AZD5363 capsule 
or tablet dosing in a partially 
fasted state (Part A). b Plasma 
glucose profiles following 
AZD5363 tablet dosing in the 
fed, partially fasted, and fasted 
states
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Part B, Day 4: Tablet in fasted state (i.e. overnight fast of minimum 8 hours, no caloric intake, and no food permitted for 4 hours after dosing)
Part B, Day 11: Tablet in fed state (i.e. dose administered 30 minutes after a 600- to 700-kcal meal and no food permitted for 4 hours after dosing)
Table 4  AEs observed in 
Part B occurring in ≥ 2 
patients in either of the two 
initial treatment periods, or 
of grade ≥ 3 severity (safety 
population)
a Includes all AEs with onset on Day 11–14 post-dose for patients who were fed according to the protocol
b AEs with onset from Day 15 up to 28 days after the date of the last dose of AZD5363; includes AEs with 
onset before Day 15 that are not captured in the other two columns
c As assessed by the investigator
Number of patients (%) Days 4–7, fasted dose
(N = 12)
Days 11–14, fed dose
(N = 10)a
Day 15  onwardb, 
partially fasted
(N = 12)
All Grade ≥ 3 All Grade ≥ 3 All Grade ≥ 3
Any AE (irrespective of causality) 5 (41.7) 2 (16.7) 6 (60.0) 4 (40.0) 12 (100.0) 7 (58.3)
Any AE(causally  relatedc) 4 (33.3) 2 (16.7) 5 (50.0) 4 (40.0) 10 (83.3) 5 (41.7)
AE by preferred term (irrespective of causality)
 Diarrhoea 2 (16.7) 1 (8.3) 3 (30.0) 2 (20.0) 8 (66.7) 1 (8.3)
 Hyperglycaemia 1 (8.3) 1 (8.3) 1 (10.0) 1 (10.0) 6 (50.0) 5 (41.7)
 Rash maculopapular 1 (8.3) 0 2 (20.0) 2 (20.0) 2 (16.7) 2 (16.7)
 Hypokalaemia 0 0 0 0 1 (8.3) 1 (8.3)
 Rash macular 0 0 1 (10.0) 1 (10.0) 1 (8.3) 0
 Rash papular 0 0 1 (10.0) 1 (10.0) 0 0
 Anaemia 1 (8.3) 0 1 (10.0) 0 1 (8.3) 1 (8.3)
 Pneumonia 0 0 0 0 1 (8.3) 1 (8.3)
 Abdominal pain 0 0 0 0 1 (8.3) 1 (8.3)
 Skin discolouration 0 0 0 0 1 (8.3) 1 (8.3)
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because of AEs, which were pneumonia, maculopapular 
rash, and papular rash (each n = 1). Six patients had dose 
interruptions, which were a result of AEs in five patients. 
Overall, median relative dose intensity was 96.2% (quar-
tile 1, 70.6%; quartile 3, 99.3%). There were no clinically 
important, treatment-related trends in clinical chemistry 
parameters.
Elevations in plasma glucose (with associated increases 
in plasma insulin and C-peptide) were observed in the 
majority of patients dosed with AZD5363 in Parts A and B 
(Fig. 3b). There was no indication of glucose elevation in 
association with AZD5363 administration during the fasted 
period (up to 4 h post-dose). Taking into consideration 
the small patient numbers and the inter-patient rather than 
intra-patient comparison, the degree of glucose elevation 
in the fed state (Part B) was similar to that in the partially 
fasted state (Part A), but the elevation occurred earlier when 
AZD5363 was administered in the fed state.
Discussion
The primary aims of this two-part, Phase 1 study were to 
evaluate whether a new tablet formulation of AZD5363 was 
comparable in PK, safety and tolerability to the original cap-
sule form and to explore potential differences between fasted 
and non-fasted (following a standard meal) administration in 
terms of the PK properties of AZD5363 tablet.
The study had a within-subject fixed-sequence design 
in each of the two parts, whereby each patient received 
AZD5363 480 mg bid as tablets (Week 1) and capsules 
(Week 2) in a 4/3 schedule (Part A) or as tablets in a fasted 
(Week 1) and fed (Week 2) state on the fourth day of the 4/3 
schedule (Part B). PK assessments were made over the 0- to 
12-h dosing interval after the morning dose on the fourth 
day of each week. Steady-state conditions were assumed to 
have been achieved on these days, based on the half life 
of AZD5363 [11]. Likewise, the 7-day period between PK 
assessments was considered sufficient not to introduce any 
important carryover effect and is thus not expected to have 
affected the PK evaluation on Day 11.
The primary tumour location did not appear to influ-
ence the systemic exposure to AZD5363. Other causes of 
between-subject variability in absorption or elimination 
capacity, such as genetic polymorphisms of key enzymes/
transporters or other metabolic differences, are not expected 
to influence the primary analyses and interpretation of this 
study as the relative bioavailability (tablet versus capsule 
and fed versus fasting, respectively) was estimated by com-
paring the systemic exposure (AUC and Cmax) within each 
patient.
Findings from Part A showed that the PK exposures 
(AUCτ and Cmax) of the AZD5363 tablet and capsule 
formulations were comparable when administered in a 
partially fasted state, and that the median tmax was approxi-
mately 1 h earlier for the tablet than for the capsule. Faster 
absorption in vivo is consistent with the more rapid dis-
solution of the tablet formulation observed in vitro (unpub-
lished data). The results from Part B showed that the extent 
of exposure was comparable when the 480 mg dose was 
given as a tablet after an overnight fast and after the test 
meal (AUCτ fed:fasted ratio 0.89; 90% CI 0.76–1.05). The 
absorption was, however, delayed, as indicated from the 
lag time in the plasma concentration–time profile, which 
is in agreement with delayed gastric emptying after food 
and the biopharmaceutical properties of AZD5363. Once 
AZD5363 has been emptied into the small intestine, its 
absorption appears to be relatively rapid and similar to that 
after an overnight or a partial fast. The delayed, and poten-
tially slower, absorption after food resulted in delayed tmax 
(median tmax of 2.0 versus 0.6 h) and lower Cmax (geomet-
ric least-squares mean ratio 0.67; 90% CI 0.55–0.82). The 
following potential limitations to the accuracy of the PK 
parameter estimation have been identified: (i) the delayed 
absorption identified in the fed state may have resulted in 
an underestimation of Cmax, and to a lesser extent, AUCτ, 
because the frequency of sampling was lower at the later 
apparent tmax in the fed state; and (ii) Cmax and AUCτ might 
be slightly biased because AZD5363 was to be administered 
in a partially fasted state on Days 1–3, but after an overnight 
fast, or with food, only on the fourth day of the 4/3 schedule. 
It can, however, be assumed that the potential bias is small 
and that the standard meal had no major effect on the bio-
availability of AZD5363.
The intra-subject variability in AUCτ and Cmax was mod-
erate (around 20% CV), as predicted or lower than antici-
pated for the sample size calculation, and generally lower 
than the inter-subject variability. This supports the results 
having adequate precision and randomized crossover or 
fixed-sequence designs being preferable to parallel-group 
designs for PK comparisons in potential future studies. 
The observed PK exposure of AZD5363 at steady state 
(Cmax and AUCτ) in this study was as expected based on 
results from an ongoing Phase 1 study of AZD5363 (Study 
D3610C00001) and in vitro dissolution data [11]. AZD5363 
exposures in this study with AZD5363 tablet dosing in the 
4/3 schedule were similar to exposures previously observed 
to correlate with tumour regression in preclinical models 
[11].
The safety and tolerability profile was not observed to 
be different between the tablet and the capsule formula-
tions and appeared to be consistent with the emerging 
safety profile for AZD5363 as a capsule derived from 
Study 1 (NCT01226316) and Study 4 (NCT01353781). 
The safety and tolerability of the tablet did not appear to 
be different between the fed and fasted states and again 
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reflected the emerging safety profile of AZD5363. Overall, 
safety observations of hyperglycaemia, diarrhoea and rash 
in this study are generally in agreement with the known 
safety profile of AZD5363 [11, 13, 14] and reflect reported 
effects of AKT inhibition [18, 19]. However, patient num-
bers were small; therefore, the safety and tolerability data 
should be interpreted with caution.
In summary, the results from this study demonstrated 
comparable PK properties of the AZD5363 tablet and cap-
sule, as well as comparable bioavailability for the tablet 
given after an overnight fast and with food. The tablet 
formulation had slower absorption in the presence of food, 
resulting in lower and later peak concentrations. The clin-
ical relevance of this food effect is currently unknown, 
hence a conservative approach has been taken; the recom-
mendation is to administer the AZD5363 tablet formula-
tion on an empty stomach, where possible, until further 
information becomes available.
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